Mereo to present its osteogenesis imperfecta study data in Orlando

Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.

Mereo noted ithas reported in May 2019, positive early 6-month data from the open label arm of the study. The company said it expects to report 12-month data on all patients enrolled in the ASTEROID study in Q4 2019.

Mereo said that the patients in the trial had not been treated with bisphosphonates in the previous 3 months or other anabolic or anti-resorptive medications in the previous 6 months.